Overview

BROKEN-SWEDEHEART-Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients registered in SWEDEHEART will be included.
Phase:
Phase 2
Details
Lead Sponsor:
Vastra Gotaland Region
Collaborator:
Sahlgrenska University Hospital, Sweden
Treatments:
Adenosine
Apixaban
Dipyridamole